AzTrials
AzTrials

Diffuse Cutaneous Systemic SclerosisPhase 2NCT04166552

Evaluation of Safety, Tolerability and Preliminary Efficacy of EHP-101 in Diffuse Cutaneous Systemic Sclerosis

A Phase 2 study of Diffuse Cutaneous Systemic Sclerosis, run by Emerald Health Pharmaceuticals at 23 sites in 4 countries.

Suspended

Paused. Enrolment is on hold for now and may resume.

Official record
Search all trials

Trial summary

The purpose of this trial is to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of EHP-101 in adult subjects with diffuse cutaneous Systemic Sclerosis (dcSSc). Read more about this study

Who is it for?
Ages 18 to 74 years
Conditions the study is for
Diffuse Cutaneous Systemic Sclerosis
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
36 participants
Where
23 sitesin 4 countries
Study dates
11 Jun 2020to Oct 2024
Phase
Phase 2
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 74 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Patients male and female ≥18 years and ≤74 years at the time of consent;
  • American College of Rheumatology/ European League Against Rheumatism 2013 Criteria for SSc; dcSSc (skin thickening on upper arms, upper legs, or trunk);
  • Documented SSc for up to 6 years from the first non-Raynaud's phenomenon with a total mRSS of ≥15;
  • No new or increased doses of immunosuppressants medications within 3 months prior to Screening;
  • Effective method of contraception for participants and their partners.

Who cannot join

  • Severe or unstable Systemic Sclerosis (SSc) or SSc with end-stage organ failure;
  • Patient with FVC <60%;
  • History of clinically significant medical condition or concurrent medical therapies that would exclude the patient, preclude participation in the clinical trial, influence response to study product, or interfere with study assessments;
  • History of gastrointestinal dysmotility requiring total parenteral nutrition or hospitalization within 6 months before Visit 1;
  • Any one of the following values for laboratory tests at screening:
  • Haemoglobin <9 g/dL;
Show all 11Show fewer
  • Neutrophils <1.0 x 10^9/L;
  • Platelets <75 x 10^9/L;
  • Estimated creatinine clearance <50 mL/min according to the Cockcroft-Gault equation;
  • Serum transaminases >2.0 x upper normal limit;
  • Total bilirubin ≥1.5 x upper limit of normal.

Trial locations and contacts

23 sites in 4 countries.

23 sites in 4 countries

United States13 sites
  • Central Florida Pulmonary Group

    Altamonte Springs, Florida, 32701

  • Northwestern University

    Chicago, Illinois, 60208

  • Cleveland Clinic

    Cleveland, Ohio, 44195

  • Care Access Research - Huntington

    Huntington Beach, California, 92648

  • Pacific Arthritis Care Center

    Los Angeles, California, 90045

  • UCLA Division of Rheumatology

    Los Angeles, California, 90095

  • Life Clinical Trials

    Margate, Florida, 33063

  • Novel Clinical Research Center

    Miami, Florida, 33186

  • University of Minnesota

    Minneapolis, Minnesota, 55455

  • Rutgers, The State University of New Jersey

    New Brunswick, New Jersey, 08901

  • Yale University

    New Haven, Connecticut, 06511

  • Arizona Arthritis & Rheumatology Associates, P.C.

    Phoenix, Arizona, 85032

  • Inland Rheumatology Clinical Trials

    Upland, California, 91786

Other trials in United States

Australia6 sites
  • Royal Adelaide Hospital

    Adelaide, 5000

  • Royal Prince Alfred Hospital

    Camperdown, 2050

  • Footscray Hospital

    Footscray, 3011

  • Griffith University

    Gold Coast, 9726

  • Fiona Stanley Hospital

    Murdoch, 6150

  • Westmead Hospital

    Sydney, 2145

Other trials in Australia

Puerto Rico3 sites
  • Centro Reumatologico

    Caguas, 00725

  • Mindful Medical Research

    San Juan, 00918

  • University of Puerto Rico, Medical Sciences Campus

    San Juan, 00935

Other trials in Puerto Rico

New Zealand1 site
  • Wellington Hospital

    Wellington, 6021

Other trials in New Zealand

About this study

Official title: A Phase IIa, Double-Blind, Randomised, Intracohort Placebo-Controlled, Multicentre Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of EHP-101 in Patients With Diffuse Cutaneous Systemic Sclerosis

The purpose of this trial is to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of EHP-101 in adult subjects with diffuse cutaneous Systemic Sclerosis (dcSSc).

Read the detailed description

An interventional, double-blind, randomized, intracohort placebo-controlled design will be used to test safety, tolerability, pharmacokinetics, and preliminary efficacy of EHP-101 in 36 patients ≥ 18 and ≤ 74 years of age with documented dcSSc. There is a screening period of 28 days, 84 days treatment period, and 28 days follow-up.

Being tested
Patients will be randomized to receive EHP-101 or Placebo
Keywords
Scleroderma, Systemic sclerosis, EHP-101 Oral Solution, dcSSc, diffuse, pathological processes, connective tissue disease, skin disease
Medical subject headings
Scleroderma, Diffuse, Scleroderma, Systemic, Pathologic Processes, Connective Tissue Diseases, Skin Diseases

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Patients will be randomized to receive EHP-101 or PlaceboDrug

    EHP-101 or placebo will be taken once a day

  • Patients will be randomized to receive EHP-101 or PlaceboDrug

    EHP-101 or placebo will be taken twice a day

Study groups in NCT04166552
Study groupRoleWhat they receive
EHP-101 low dose once a dayExperimentalNot described
Receives: Drug: Patients will be randomized to receive EHP-101 or Placebo
EHP-101 low dose twice a dayExperimentalNot described
Receives: Drug: Patients will be randomized to receive EHP-101 or Placebo
EHP-101 high dose once a dayExperimentalNot described
Receives: Drug: Patients will be randomized to receive EHP-101 or Placebo
EHP-101 high dose twice a dayExperimentalNot described
Receives: Drug: Patients will be randomized to receive EHP-101 or Placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Incidence and severity of Treatment Emergent Adverse Events

    This safety outcome combines the measure of the number of subjects experiencing adverse events (AEs), the nature and severity of those AEs and their relationship to the study treatments.

    Measured: Day 113

Secondary outcomes (6)
  1. Treatment effect of EHP-101 compared to placebo as measured by the American College of Rheumatology composite response index in diffuse cutaneous Systemic Sclerosis

    The ACR CRISS exponential algorithm determines the predicted probability of improvement from baseline, incorporating change in modified Rodnan Skin Score (mRSS), Forced Vital Capacity (FVC) % predicted, physician and patient global assessments, and Scleroderma Health Assessment Questionnaire Disability Index (S-HAQ-DI). The outcome is a continuous variable between 0.0 and 1.0 (0 - 100%). Subjects are not considered improved (ACR CRISS score = 0) if they develop new: 1) renal crisis; 2) decline in FVC% predicted by 15% (relative) from baseline and confirmed after 1 month; or 3) left ventricular failure (systolic ejection fraction < 45%); or 4) new pulmonary artery hypertension on right heart catheterization requiring treatment.

    Measured: Day 85 and Day 113

  2. Treatment effect of EHP-101 compared to placebo in modified Rodnan Skin Score

    The mRSS consists of an evaluation of patient's skin thickness rated by clinical palpation using a 0-3 scale (0 = normal skin; 1 = mild thickness; 2 = moderate thickness; 3 = severe thickness with inability to pinch the skin into a fold for each of 17 surface anatomic areas of the body: face, anterior chest, abdomen, and, with right and left sides of the body separately evaluated, the fingers, forearms, upper arms, thighs, lower legs, dorsum of hands and feet. Individual values are summed and defined as the total skin score. Total score is 0 to 51.

    Measured: Day 85 and Day 113

  3. Treatment effect of EHP-101 compared to placebo in forced vital capacity percent predicted

    Forced vital capacity (FVC) is a standard pulmonary function test used to quantify respiratory muscle weakness . FVC was the volume of air that can forcibly be blown out after full inspiration in the upright position, measured in liters. Predicted forced vital capacity is based on a formula using sex, age and height of a person, and is an estimate of healthy lung capacity. Percent of predicted FVC = (observed value)/(predicted value) * 100%

    Measured: Day 85 and Day 113

  4. Treatment effect of EHP-101 compared to placebo in physician global assessment score

    The Physician Global Assessment of disease activity will be performed using a segmented numerical version of the visual analogue scale in which the physician selects a whole number (0-10 integers) that best reflects the overall disease activity. The numerical rating score is anchored by 2 verbal descriptors, one of "no disease activity" (score of 0) and one of "worse imaginable disease activity" (score of 10), with numbers 1-9 spaced equidistance in between. The physician will select an integer to describe disease activity. The recall period is one week.

    Measured: Day 85 and Day 113

  5. Treatment effect of EHP-101 compared to placebo in patient global assessments score

    The Patient Global Assessment will be performed with a segmented numerical version of the visual analogue scale in which the subject selects a whole number (0-10 integers) that best reflects the overall disease activity. The numerical rating score is anchored by two verbal descriptors, one of "no disease activity" (score of 0) and one of "worse imaginable disease activity" (score of 10), with numbers 1-9 spaced equidistance in between. The subject will select an integer to describe disease activity. The recall period is one week.

    Measured: Day 85 and Day 113

  6. Treatment effect of EHP-101 compared to placebo in Scleroderma Health Assessment Questionnaire - Disability Index

    S-HAQ-DI includes 8 sections: dressing, arising, eating, walking, hygiene, reach, grip, and activities. There are two or three questions for each section. Scoring within each section is from 0 (without any difficulty) to 3 (unable to do). The eight scores of the eight sections are summed and divided by 8. If one section is not completed by a subject, the summed score is divided by 7. As such, maximum scores can vary with a min of 0. The result is the DI, the disability index or functional disability index. The recall period is one week.

    Measured: Day 85 and Day 113

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted18 Nov 2019
  2. Study start11 Jun 2020
  3. Primary completionJul 2024 (estimated)
  4. Study completionOct 2024 (estimated)

Why it stopped: Sponsor ceasing all operations due to company's shut down

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
This is a dose escalation double-blind intracohort trial starting with Cohorts 1 and 2 commencing in parallel and then Cohorts 3 and 4 commencing in parallel
Masking
Double blind
Who is masked
Participant, Investigator
Enrolment
36 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04166552
Sponsor's protocol ID
EHP-101-SS01
Status last verified
Sep 2022
First submitted
6 Nov 2019
Last updated
21 Sep 2023
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A Phase 2 study of Diffuse Cutaneous Systemic Sclerosis, run by Emerald Health Pharmaceuticals at 23 sites in 4 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: paused, as of the sponsor's last update on 21 Sep 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 23 sites in United States, Australia, Puerto Rico, New Zealand. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Incidence and severity of Treatment Emergent Adverse Events (time frame: Day 113). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Sep 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in